<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909155</url>
  </required_header>
  <id_info>
    <org_study_id>0600B-100953</org_study_id>
    <nct_id>NCT00909155</nct_id>
  </id_info>
  <brief_title>Brain Imaging Techniques That Predict Antidepressant Responsiveness</brief_title>
  <acronym>WyethKolden</acronym>
  <official_title>Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine
      treatment and do changes in selective structures, such as the amygdala, predict treatment
      response?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single site, controlled, double-blind study of outpatients. There are two arms:

        1. Forty participants who have a current Diagnostic and Statistical Manual of Mental
           Disorders, 4th edition, text revised (DSM-IV-TR) diagnosis of Major Depression will be
           recruited. These subjects will be randomized to receive one of two antidepressant
           medications: Fluoxetine or Venlafaxine ER for the duration of the study. Subjects will
           gradually be titrated onto the medications and will be seen in the clinic up to 18 times
           for medication checks, to monitor side effects and depressive symptoms, including
           suicidal ideation. In the event of suicidal ideation, subjects will be withdrawn from
           the study and referred for immediate treatment.

        2. Twenty normal control subjects with no current or past DSM-IV-TR diagnosis and will
           receive no medication. Normal control subjects will have up to 5 visits while in the
           study.

      Subjects will contact study staff to complete a phone screen and then eligible subjects will
      complete a clinic screen. Subjects will then be scheduled to attend the magnetic resonance
      imaging (MRI) simulation visit and if subjects continue to meet entrance criteria, they will
      be scheduled for the first MRI. Following the first MRI, subjects in the medication
      conditions will begin receiving medication.

      All subjects will undergo 3 functional magnetic resonance imaging (fMRI)s during the study:
      at the beginning of the study, approximately 8 weeks and 26 weeks later. During the MRI,
      subjects will view slides with positive and negative emotional content. Subjects will
      complete various clinical interviews or rating scales assessing mood and side effects at each
      of the visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales</measure>
    <time_frame>Study entry, 2 months, and at end of study (6 mos)</time_frame>
    <description>Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).
Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.</measure>
    <time_frame>At study entry, 2 months and end of study (6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitals</measure>
    <time_frame>each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Depressed; Venlafaxine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depressed; Fluoxetine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine ERT</intervention_name>
    <description>Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.</description>
    <arm_group_label>Depressed; Venlafaxine treatment</arm_group_label>
    <other_name>Effexor ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d</description>
    <arm_group_label>Depressed; Fluoxetine treatment</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intervention Group:

               -  Right-handed,

               -  Be able to lie still on their back for about 120 minutes,

               -  Meet DSM-IV criteria for major depression (single or recurrent),

               -  Have had depressive symptoms for at least 1 month prior to screen visit,

               -  Must score an 18 or above on the Hamilton-D at both the initial screening visit
                  and first fMRI scanning session,

               -  Able to understand and speak English.

          -  Control Group: same as above with the exception of no diagnosis of psychiatric
             disorder.

        Exclusion Criteria:

          -  Any history of seizures,

          -  Current medical disorders that might make interpretation of scan data difficult,

          -  Diabetes requiring insulin treatment,

          -  A serious heart disorder or subjects who have had a heart attack within the last 3
             months,

          -  Subjects who meet DSM-IV criteria for alcohol/drug abuse or dependence within the last
             six months,

          -  Other current DSM-IV Axis I or Axis II diagnoses,

          -  A personal or family history of bipolar disorder,

          -  Current use of medication that affects central nervous system (CNS) function,

          -  Participation in the last 30 days in a clinical study involving an investigational
             drug,

          -  A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or
             persons with electronic implants, such as cardiac pacemakers. The magnetic field
             generated by the MRI machine can cause a displacement or malfunctioning of these
             devices.

          -  A subject who is claustrophobic,

          -  Female subjects who are pregnant,

          -  A subject at serious risk for suicide,

          -  Diagnosis of cancer in the past 3 years and/or has active neoplastic disease,

          -  Nonresponse to 2 adequate trials of antidepressant treatment,

          -  Nonresponse to 2 adequate trials of an empirically supported psychotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Kolden, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Madison Psychiatry Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Peterson, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Madison Psychiatry Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Madison Psychiatry Department</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Heller AS, Johnstone T, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ. Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. JAMA Psychiatry. 2013 Nov;70(11):1181-9. doi: 10.1001/jamapsychiatry.2013.2430.</citation>
    <PMID>24173657</PMID>
  </results_reference>
  <results_reference>
    <citation>Heller AS, Johnstone T, Light SN, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ. Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment. Am J Psychiatry. 2013 Feb;170(2):197-206. doi: 10.1176/appi.ajp.2012.12010014.</citation>
    <PMID>23223803</PMID>
  </results_reference>
  <results_reference>
    <citation>Light SN, Heller AS, Johnstone T, Kolden GG, Peterson MJ, Kalin NH, Davidson RJ. Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder. Biol Psychiatry. 2011 Nov 15;70(10):962-8. doi: 10.1016/j.biopsych.2011.06.031. Epub 2011 Aug 25.</citation>
    <PMID>21867991</PMID>
  </results_reference>
  <results_reference>
    <citation>Heller AS, Johnstone T, Shackman AJ, Light SN, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ. Reduced capacity to sustain positive emotion in major depression reflects diminished maintenance of fronto-striatal brain activation. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22445-50. doi: 10.1073/pnas.0910651106. Epub 2009 Dec 22.</citation>
    <PMID>20080793</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Currently Depressed Subjects: Venlafaxine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT).
Venlafaxine ERT: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.</description>
        </group>
        <group group_id="P2">
          <title>Currently Depressed Subjects: Fluoxetine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Fluoxetine
Fluoxetine: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d</description>
        </group>
        <group group_id="P3">
          <title>Control (Non-psychiatric Subjects)</title>
          <description>Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Currently Depressed Subjects: Venlafaxine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Venlafaxine ERT
Venlafaxine ERT: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.</description>
        </group>
        <group group_id="B2">
          <title>Currently Depressed Subjects: Fluoxetine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Fluoxetine
Fluoxetine: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d</description>
        </group>
        <group group_id="B3">
          <title>Control (Non-psychiatric Subjects)</title>
          <description>Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data from the fluoxetine and venlafaxine groups were combined for analysis as individual groups not large enough to provide sufficient statistical power to identify treatment differences between groups.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.74" spread="11.46"/>
                    <measurement group_id="B2" value="33.14" spread="10.71"/>
                    <measurement group_id="B3" value="31.31" spread="14.22"/>
                    <measurement group_id="B4" value="31.65" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales</title>
        <description>Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).
Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety).</description>
        <time_frame>Study entry, 2 months, and at end of study (6 mos)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Currently Depressed Subjects: Venlafaxine</title>
            <description>Currently depressed subjects; Randomized medication treatment with Venlafaxine ERT
Venlafaxine ERT: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.</description>
          </group>
          <group group_id="O2">
            <title>Currently Depressed Subjects: Fluoxetine</title>
            <description>Currently depressed subjects; Randomized medication treatment with Fluoxetine
Fluoxetine: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d</description>
          </group>
          <group group_id="O3">
            <title>Control (Non-psychiatric Subjects)</title>
            <description>Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales</title>
          <description>Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).
Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAMD T0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.07" spread="1.94"/>
                    <measurement group_id="O2" value="21.36" spread="2.71"/>
                    <measurement group_id="O3" value="1" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAMA T0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.07" spread="3.37"/>
                    <measurement group_id="O2" value="15.57" spread="3.82"/>
                    <measurement group_id="O3" value="NA">HAMA not collected on control subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAMD 2months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="4.5"/>
                    <measurement group_id="O2" value="10.15" spread="4.52"/>
                    <measurement group_id="O3" value="1.25" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAMA 2months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="4.55"/>
                    <measurement group_id="O2" value="8.54" spread="4.86"/>
                    <measurement group_id="O3" value="NA">HAMA not collected on control subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAMD 6months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3.67"/>
                    <measurement group_id="O2" value="7.33" spread="4.92"/>
                    <measurement group_id="O3" value="1.64" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAMA 6months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="3.36"/>
                    <measurement group_id="O2" value="5.89" spread="3.86"/>
                    <measurement group_id="O3" value="NA">HAMA not collected on control subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.</title>
        <time_frame>At study entry, 2 months and end of study (6 months)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitals</title>
        <time_frame>each visit</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Currently Depressed Subjects; Venlafaxine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Venlafaxine ERT.
Venlafaxine ERT: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.</description>
        </group>
        <group group_id="E2">
          <title>Currently Depressed Subjects; Fluoxetine</title>
          <description>Currently depressed subjects; Randomized medication treatment with Fluoxetine
Fluoxetine: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d</description>
        </group>
        <group group_id="E3">
          <title>Control (Non-psychiatric Subjects)</title>
          <description>Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively small number of subjects. Not powered statistically to determine if either treatment arm (fluoxetine or venlafaxine) is superior.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Peterson</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608 265 8130</phone>
      <email>mpeterson2@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

